Aspirin and primary prevention: BHS reaffirms its guidance

BMJ (Online)

Volumn 340, Issue 7745, 2010, Pages 494-

  Sever, Peter S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT;

CARDIOVASCULAR RISK; DIABETES MELLITUS; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; LETTER; LOW DRUG DOSE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; STROKE; UNITED KINGDOM;

ASPIRIN; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; STROKE;

EID: 77749306387     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c1183     Document Type: Letter

References (1)

1. De Berardis G, Sacco M, Strippoli GFM, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531. (6 November.)[Abstract/Free Full Text]